You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基石藥業-B(02616.HK):合作伙伴施維雅在ASCO年會上公佈拓舒沃®(艾伏尼布片)治療IDH1突變急性髓系白血病的最新積極數據
格隆匯 06-07 08:04

格隆匯6月7日丨基石藥業-B(02616.HK)發佈公吿,基石藥業合作伙伴施維雅近日宣佈,已在2023年美國臨牀腫瘤學年會(ASCO)上公佈拓舒®(艾伏尼布片)聯合化療阿扎胞苷治療新診斷急性髓系白血病(AML)的全球III期研究AGILE的更新數據,以及針對拓舒®療效分析的最新數據。拓舒®是全球首個針對突變異檸檬酸脱氫酶-1(IDH1)的特異性靶向療法。AGILE更新數據顯示,與阿扎胞苷聯合安慰劑相比,拓舒®聯合阿扎胞苷可明顯改善患者的總生存期(OS)。近日,拓舒®也已獲得歐盟委員會批准,成為歐洲首個IDH1抑制劑。

關鍵亮點包括AGILE III期研究更新數據顯示,拓舒沃®聯合阿扎胞苷的中位總生存期延長至29.3個月,並且進一步證實拓舒沃®作為新診斷急性髓系白血病(AML)一線治療所帶來的持續獲益。此外,通過對I期擴展研究的分析,識別出對拓舒沃®治療產生超級應答的AML患者的臨牀和分子特徵。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account